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Abstract
Objectives: We evaluate safety of routine vaccination among adults infected with human 
immunodeficiency virus (HIV) in five healthcare organizations in the United States.
Methods: We conducted a retrospective cohort study of HIV-infected adults who received 
inactivated influenza vaccines, hepatitis B vaccines, pneumococcal vaccines, or tetanus, 
diphtheria, and acellular pertussis vaccines between 2002 and 2013. We conducted self-controlled 
case series analysis to estimate the relative risk (RR) for 11 pre-specified adverse events (AEs) 
requiring medical attention.
Results: Among 20,417 HIV-infected adults (90.2% male), a total of 137,674 vaccine doses were 
administered. Based on ICD-9 codes, we detected an increased risk of cellulitis and infection (RR: 
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1.18, 95% CI:1.03–1.35) among all patients, and an increased risk of stroke/cerebrovascular 
diseases among patients with an HIV viral load >10,000 copies/ml (adjusted RR: 3.94, 95% CI: 
1.32–11.72). Further analyses on chart confirmed cases of stroke/cerebrovascular diseases 
indicated no statistically significant increased risk (adjusted RR: 1.72, 95% CI: 0.41–7.24). There 
was no evidence of increased risk for other AEs following routine vaccination in HIV-infected 
adults.
Conclusions: Routinely administered vaccines are generally safe for HIV-infected adults.
Keywords
Vaccine safety; HIV; Vaccine Safety Datalink
1. Introduction
Due to impaired host immune defenses, persons infected with human immunodeficiency 
virus (HIV) have an increased risk and greater severity of vaccine-preventable infections, 
resulting in high morbidity and mortality. HIV-infected persons are more susceptible to 
influenza and experience prolonged duration and increased severity of illness and have 
higher rates of hospitalization [1–4]. They also have a markedly higher risk of invasive 
pneumococcal disease despite immune reconstitution and suppression of HIV replication 
with combination antiretroviral therapy (cART) [5–7]. Individuals with co-infection of HIV 
and hepatitis B virus (HBV) have increased rates of HBV replication and accelerated disease 
progression, with increased incidence of liver fibrosis, cirrhosis, end-stage liver disease, 
hepatocellular carcinoma, and liver-related deaths compared with hepatitis B mono-infected 
patients [8]. A recent study reported an annual incidence of pertussis among unvaccinated 
HIV-infected adults of 10.5–17.5% [9]. As CD4+ T helper cells are critical for the clearance 
of pertussis [10], HIV-infected individuals could have more severe or prolonged pertussis 
infections than the general population [11–13]. The Advisory Committee on Immunization 
Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) recommends all 
HIV-infected adults receive inactivated vaccines against influenza, pneumonia, hepatitis B, 
and tetanus, diphtheria, and acellular pertussis, regardless of CD4+ T-cell count and age 
[14–16].
Despite the increased risk for infections and the widespread availability of vaccines, reported 
vaccine coverage rates among HIV-infected adult patients are low [17–21]. Data from two 
studies in the United States suggested that influenza vaccination coverage among HIV-
infected patients ranged between 25% and 43%, and that patients with a lower CD4+ T-cell 
count and higher HIV RNA viral load were less likely to have received influenza vaccine 
[19,20].
Reasons for the low vaccine coverage rates among HIV-infected patients are likely 
multifactorial [22], including fear of side effects and adverse impact on HIV disease [23]. 
However, there are no substantive data to support the notion that influenza, pneumococcal, 
and hepatitis B vaccines adversely affect the overall health of HIV patients or accelerate 
disease progression [24–30]. Currently, safety data for tetanus-diphtheria and tetanus-
diphtheria-acellular pertussis vaccines (Td/Tdap) are not available among HIV-infected 
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adults. Furthermore, most of the previous vaccine safety studies among HIV-infected 
patients had small sample sizes and were not powered to detect rare adverse events (AEs). 
Those previous studies used HIV-uninfected populations as a comparison group, thus 
estimated risk ratio of vaccine induced AEs is subject to confounding by the effect of 
impaired immune response in HIV-infected patients because the underlying risks in HIV-
infected individuals are expected to be different from that in HIV-uninfected patients.
Within a large, community-based, diverse cohort of HIV-infected adults receiving care from 
2002 to 2013, we sought to use an self-controlled study design to examine whether there was 
an increased risk of pre-specified AEs following receipt of recommended inactivated 
vaccines for HIV-infected adults, including inactivated influenza vaccine (including 
monovalent H1N1pdm09 vaccine), 23-valent pneumococcal polysaccharide vaccine 
(PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13), HBV vaccine, Td, and 
Tdap, and to assess whether the risk differed by level of CD4+ T-cell count or HIV RNA 
viral load at vaccination.
2. Methods
2.1. Study setting
This study was conducted in the population of a multi-site vaccine safety project, Vaccine 
Safety Datalink (VSD). We have used the large administrative data and electronic health 
records (EHR) of the VSD to study immunization safety in the United States, which captures 
comprehensive medical and immunization histories for more than 10.7 million people 
annually, representing roughly 3% of the population in the United States. Results from this 
project have been used to inform policymakers and healthcare practitioners about a variety 
of vaccine safety-related topics. The protocol for this study was reviewed and approved by 
the Institutional Review Board at each participating site.
2.2. Study design and study population
We included all adults (>18 years) infected with HIV who received at least one of the 
vaccines of interest (inactivated influenza vaccine, PPSV23, PCV13, HBV vaccine, Td, and 
Tdap) during January 2002 through December 2013 at five integrated health care 
organizations of VSD. We identified HIV-infected patients through centralized HIV patient 
registries in EHR at three participating sites and by positive Western Blot test results at the 
other two sites. Vaccination information was ascertained through the vaccine file. 
Continuous membership at the health systems (allowing a 31-day gap for administrative 
delays) in the one year prior to vaccination was required to allow ascertainment of incident 
status of AEs. All vaccines administered in the participating sites were recorded in the EHR 
routinely. Information on vaccines received outside of the healthcare systems were captured 
through claims data, and as a standard practice, providers routinely collect the information 
on vaccines received out of the healthcare systems and back enter the information in the 
EHR. The membership requirement also allowed assessment of the baseline CD4+ T-cell 
count and HIV RNA viral load measured in the six months prior to and including the date of 
the vaccination. All information was linked through the patient unique ID.
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We used the self-controlled case series (SCCS) design to evaluate the association between 
vaccination and risk of pre-specified incident acute AEs among eligible HIV-infected 
patients. An incident AE was defined as a new diagnosis following vaccination, i.e. no 
history of the same diagnosis in previous 30 days for local allergic reactions and anaphylaxis 
and in the last 12 months for other severe acute events. In SCCS analyses, each person 
serves as his/her own comparison: for each AE, a pre-specified risk window was defined 
following the date of the index vaccination (day 0), and a comparison window was defined 
as a time period immediately following the risk window. The observational period for each 
vaccination encounter was censored at membership disenrollment or upon receipt of another 
vaccine of interest. The SCCS design adjusts for non-time varying confounders, such as sex 
and race/ethnicity. Given the short follow-up period and the acute nature of the AEs of 
interest in this study, we can also assume that each individual’s age, socioeconomic status 
(education, income), HIV disease severity level (e.g. CD4+ T-cell count, HIV RNA viral 
load), status of comorbidities, and cART use did not vary substantially across the risk and 
control windows.
2.3. Outcomes
The primary outcomes for this study included 11 pre-specified acute AEs after vaccination 
that were categorized into 5 groups: (1) systemic reactions (anaphylaxis); (2) local reactions 
(cellulitis and infection, allergic reaction); (3) cardiovascular events (acute and subacute 
myocardial infarction, acute pericarditis, acute myocarditis, cardiomyopathy, and heart 
failure); (4) stroke and cerebrovascular diseases, venous thromboembolism (VTE); and (5) 
meningitis, encephalitis, and encephalopathy. We selected these AEs based on previous 
vaccine safety studies conducted among general populations. We also included acute 
cardiovascular events, stroke, cerebrovascular diseases, and VTE to explore whether there is 
an elevated risk following vaccinations, as people living with HIV may experience an 
increased risk of vascular disease. The risk window was determined based the estimate of a 
plausible incubation period between vaccination and the onset of each AE, a method 
generally used in vaccine safety studies. To be consistent with the previous vaccine safety 
studies, we defined the risk window for anaphylaxis as 0–6 days. We defined the risk 
window for local reactions as 1–7 days, and 1–42 days for all other AEs of interest. We 
excluded diagnosis codes assigned on the day of vaccination (Day 0) from analysis of safety 
signals for local reactions and other AEs except for anaphylaxis, because diagnosis codes 
assigned on day 0 usually represent pre-existing conditions based on our experiences in 
previous VSD studies. For each AE in this study, we defined the comparison window as two 
times the length of the corresponding risk window immediately following the risk window. 
The specific AEs, risk windows, International Classification of Diseases, 9th revision 
(ICD-9) codes, and care settings (inpatient, emergency department [ED], outpatient) used to 
identify these events are provided in Appendix Table 1.
2.4. Analysis
We calculated the total number and the average number of vaccine doses received per person 
by vaccine type. We reported the number of incident AEs identified by ICD-9 codes during 
pre-specified risk and comparison windows. Because each HIV-infected patient served as 
their own control in the SCCS analysis, we used conditional Poisson regression models to 
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estimate relative risk (RR) for each AE by comparing the incidence in the risk window vs. 
the incidence in the comparison window. Multiple doses administered on different dates 
were treated as repeat exposures with assumption of same risk for each exposure in the 
analyses [31]. Multiple vaccines administered concomitantly on the same day were treated 
as one exposure in the main analysis of AE following any vaccination. Concomitant 
vaccines were accounted for in the subgroup analyses by vaccine type. To account for 
potential confounding by clustering of seasonal vaccination (e.g., influenza vaccines given 
during winter months), analyses were adjusted for seasonality for AEs with a risk window ≥ 
14 days. Analyses were further stratified by vaccine type, receipt of concomitant vaccines, 
baseline CD4+ T-cell count (<200, 200–499, ≥500 cells/mm3), and HIV RNA viral load 
(undetected or ≤200, 201–10,000, >10,000 copies/ml). The cut-off values of the categorical 
stratification were determined by the widely used standard ranges for determining the levels 
of immune function and control of HIV disease (the lower the CD4+ T-cell count, the more 
severely impaired immune function; the higher the HIV RNA viral load, the worse viral 
suppression). The 95% confidence intervals (CI) of RRs that did not overlap with 1 were 
considered statistically significant. Serious outcomes with a statistically significant increased 
risk were chart reviewed to confirm the diagnosis and symptom onset date. Additional SCCS 
analyses were conducted based on chart-confirmed AE cases and symptom onset date. We 
performed statistical analyses using SAS, version 9.3 (SAS Institute, Cary, NC).
3. Results
We identified 20,417 eligible HIV-infected adult vaccinees who received a total of 137,674 
vaccine doses on 124,645 unique dates (a person could receive more than one vaccine on 
one day) during 2002–2013. Most of the HIV-infected patients in this study were males 
(~90%). The age of HIV-infected patients in this study ranged between 18 and 96 years, with 
a mean age of 51 years (standard deviation = 11.5). During the study period, the study 
population received 88,575 doses of influenza vaccine, 12,693 doses of HBV vaccine, 
23,092 doses of PPSV23 or PCV13, and 13,314 doses of Td or Tdap. On average, each 
patient received approximately 7 doses of various vaccines during the study period, with an 
average of 4.8 doses of influenza vaccine, 2.6 doses of HBV vaccine, 1.5 doses of PPSV23/
PCV13, and 1.1 doses of Td/Tdap among those who received any of those vaccines. A 
CD4+ T-cell count measurement within 6 months prior to vaccination was available for 
93.8% of the vaccination dates, and 93.5% had a HIV RNA viral load measurement.
Among all patients receiving any type of vaccine of interest, a small elevated risk for 
cellulitis and infection in the 1–7 days following vaccination was detected (RR: 1.18, 95% 
CI: 1.03–1.35) (Table 1). There was no significant increased risk for other AEs following 
vaccination. In analyses stratified by whether patients received more than one type of 
vaccine on the same day (i.e., concomitant vaccination, n = 11156, 9% of the total sample), a 
slightly elevated risk for cellulitis and infection was also observed among patients who did 
not receive concomitant vaccine (RR: 1.17, 95% CI: 1.02–1.34); while the point estimate of 
the relative risk among those who received concomitant vaccination was slightly higher, but 
it was not statistically significant (RR: 1.35, 95% CI: 0.86, 2.11). In stratified analyses by 
vaccine type (influenza, HBV, or bacterial vaccines including PPSV23/PCV13 and Td/
Tdap), an elevated risk for cellulitis and infection was only observed among patients who 
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received bacterial vaccines (RR: 1.88, 95% CI: 1.48–2.40), while there was no significant 
risk detected after either influenza vaccination or HBV vaccination. We did not observe an 
elevated risk of any other AE regardless of concomitant vaccination or the type of vaccine.
Baseline CD4+ T-cell count was < 200 cells/mm3 in 8% of patients and ≥ 500 cells/mm3 in 
53% of patients. In analyses stratified by baseline CD4+ T-cell count, a small but 
statistically significant risk for cellulitis was observed among patients with baseline CD4+ 
T-cell count ≥ 500 cells/mm3 (RR: 1.25, 95% CI: 1.03–1.52). We also observed a small risk 
of cellulitis among patients with baseline CD4+ T-cell count < 200 cells/mm3 (RR: 1.11, 
95% CI:0.75–1.65), but the association did not reach statistical significance, potentially due 
to the small sample size of this subgroup (n = 9,216). No significant elevated risk was 
identified for other AEs in analyses stratified by baseline CD4+ T-cell count; however, we 
observed a non-statistically significant elevated risk for stroke and cerebrovascular diseases 
(adjusted RR: 1.79, 95% CI: 0.65–4.91) among patients with a baseline CD4+ T-cell count < 
200 cells/mm3. In stratified analyses by HIV RNA viral load, we detected a significantly 
elevated risk for stroke and cerebrovascular diseases (RR: 3.94, 95% CI: 1.32–11.72) among 
patients with a baseline viral load greater than 10,000 copies/ml, based on data from 11,339 
unique vaccination dates (Table 2). There was no elevated risk among those with a baseline 
viral load < 10,000 copies/ml. When we further stratified the analysis by vaccine type 
among those who had a baseline HIV RNA viral load greater than 10,000 copies/ml, we 
observed elevated risks for stroke and cerebrovascular diseases following influenza vaccine, 
HBV vaccine, and PPSV23/PCV13, but the estimates for adjusted RRs were not statistically 
significant and the confidence intervals were wide (Table 3). The adjusted RR for stroke and 
cerebrovascular diseases following Td/Tdap vaccine among those with viral load greater 
than 10,000 copies/ml was not estimated, as there were no cases identified during the 
comparison window.
We performed a series of analyses to explore the elevated risk for stroke and cerebrovascular 
diseases. First, since higher HIV RNA viral load is an indicator for uncontrolled HIV disease 
and may be associated with other underlying risk factors for stroke, we checked the stability 
of viral load during time periods across pre-vaccination and post-vaccination periods 
(including risk and comparison windows, when available). About 90% of the patients had 
stable viral load values during the one year prior to vaccination and the viral load values 
were similar in the risk and comparison windows as compared to that prior to vaccination. 
SCCS analyses stratified by whether patient’s viral load remained stable did not alter the 
results among those with a baseline viral load greater than 10,000 copies/ml (data not 
shown), and the estimated RRs remained elevated but not statistically significant. Second, 
we performed separate analyses only on stroke cases based on ICD-9 codes, and still 
observed an elevated RR in patients with a baseline viral load greater than 10,000 copies/ml 
(not statistically significant).
Since stroke and cerebrovascular diseases were considered serious AEs following 
vaccination, we performed manual chart review to confirm the diagnosis and symptom onset 
date for all stroke and cerebrovascular disease cases identified by ICD-9 codes. Chart review 
of 131 presumptive cases confirmed 82 as definite cases (62.6%) and 17 (13.0%) as possible 
cases. Among the 82 confirmed cases, 57 were new-onset cases and 10 were recurrent cases. 
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Another 15 cases either were coded for a historical diagnosis or lacked information on 
symptom onset were excluded. Among the confirmed new-onset and recurrent cases (n = 
67), 20 cases had a symptom onset date within the risk window, 46 cases had a symptom 
onset date within the comparison window, and one case was excluded as the symptom onset 
date was prior to the risk window. None of the confirmed cases had documented HIV 
treatment regimen change around the time of vaccination or the diagnosis. We then 
conducted SCCS analyses on the 66 new-onset and recurrent cases confirmed by chart 
review. The results showed no elevated risk for stroke and cerebrovascular disease following 
vaccination in the overall cohort (RR: 0.76, 95% CI: 0.51, 1.12) and a RR of 0.53 (95% CI: 
0.31–0.90) among patients with achieved viral suppression (viral load ≤ 200 copies/ml), and 
we observed a RR of 1.72 (95% CI: 0.41–7.24, not statistically significant) for stroke and 
cerebrovascular disease among patients with the baseline HIV RNA viral load greater than 
10,000 copies/ml (Table 4).
We further examined the characteristics of the eight chart-confirmed cases (4 in the risk 
window on day 0, 12, 36, 39, and 4 in the comparison window on day 70, 74, 95, 105) 
among patients with baseline viral load greater than 10,000 copies/ml (Appendix Table 2). 
Among the four cases that occurred in the risk window (two new- onset and two recurrent 
cases), two of them were stroke cases and two were transient ischemic attack (TIA) cases; 
while among the four cases in the comparison window (all were new-onset cases), three 
were stroke cases and one was a TIA case. There was no clustering of timing of onset within 
the risk and comparison windows by graphically investigating the timing of the events 
relative to vaccination. All eight cases received either influenza (two cases in the risk 
window and three cases in the comparison window) or hepatitis B vaccine (two cases in the 
risk window and one case in the comparison window). Two cases in the risk window and one 
case in the comparison window had documented evidence of potential risk factors for stroke/
cerebrovascular diseases.
4. Discussion
In a large cohort of HIV-infected adults, we found that routinely administered vaccines 
recommended for HIV-infected adults are generally safe. There was a mild increased risk for 
cellulitis and infection in the 1–7 days following vaccination, particularly among patients 
with a baseline CD4+ T-cell count greater than 500 cells/mm3, and among those who 
received bacterial vaccines including PPSV23, PCV13, Td and Tdap. A previous VSD study 
reported an increased risk of inflammatory AEs at the injection site following Tdap 
vaccination among the general elderly population [32]. A case report described cellulitis-like 
reaction following PPSV23 vaccination among five adults [33]. In addition, injection site 
reactions and cellulitis are also listed in the vaccine package insert of some Td, Tdap and 
pneumococcal vaccines as reported adverse events following vaccination [34]. Our findings 
of the elevated risk of cellulitis and infection following these vaccines were consistent with 
those previous reports. We did not find an elevated risk for the other AEs of interest 
following vaccination in the complete study sample. The findings in this study provided 
reassurance that those vaccines currently recommended for HIV-infected patients are 
generally safe.
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We did not observe an increased risk of stroke and cerebrovascular diseases among the 
overall study population. However, a significant elevated risk was detected in analyses based 
on ICD-9 codes for stroke and cerebrovascular diseases among patients with baseline HIV 
RNA viral load greater than 10,000 copies/ml. The occurrence of the occurrence of incident 
stroke and cerebrovascular diseases following vaccination was rare, and we did not observe 
statistically significant findings in stratified analysis by vaccine type or after we limited the 
analysis to chart-confirmed new-onset and recurrent cases. The RR point estimate remained 
greater than 1 (RR = 1.72) with a wide confidence interval in the analysis using chart-
confirmed cases, the small sample size may have limited the statistical power to detect a 
small to moderate risk, thus the wide confidence interval. The risk estimate translated to an 
absolute risk difference of 4 cases (95% CI: 14–21 cases) per 1,000,000 person-days of 
follow-up among patients with baseline HIV RNA viral load greater than 10,000 copies/ml. 
Although the absolute disease burden may be small, stroke is a serious event. We do not 
have adequate evidence to reject the null hypothesis of the elevated risk for stroke and 
cerebrovascular disease in HIV-infected patients with a high HIV RNA viral load. Further 
follow-up studies with a larger sample size of this subgroup of patients may be warranted.
This study utilized comprehensive EHR data spanning over 10 years from 5 large U.S. 
health care organizations with diverse populations [35]. We included a large number of 
vaccination encounters among over 20,000 adults with HIV. Because participating sites 
deliver integrated care, we were able to ascertain diagnoses of AEs at outpatient, inpatient, 
and ED settings, and capture CD4+ T-cell counts and HIV RNA viral load measurements at 
and around the time of vaccination. The SCCS design allowed HIV-infected patients to serve 
as their own comparison group, minimizing potential confounding caused by certain 
demographic and clinical risk factors during a relative short follow up. In addition, because 
we were able to identify all HIV patients who received vaccines of interest during the study 
period and ascertained the vaccination records and diagnosis of AEs using the 
comprehensive EHR at all participating sites, our analysis was less likely to be affected by 
patient selection bias and recall bias that are often concerns for studies that rely on patient 
recruitment and self-reported vaccination and AEs.
However, there are some potential limitations that should be considered. First, there were no 
HIV medication data in our study database. However, we investigated HIV medication use 
among chart-reviewed stroke/cerebrovascular disease cases, and none of the chart-confirmed 
cases had a documented HIV treatment regimen change around the time of vaccination or 
the diagnosis. Second, the sample size of HIV-infected patients in stratified analyses might 
not be adequate to detect a small increased risk of AEs associated with vaccination. Third, 
although we found that a majority of patients had a stable viral load before and after 
vaccination, the study could not evaluate whether there were increases in viral load 
immediately following vaccination, as many patients had CD4+ T-cell count and viral load 
measured routinely at 3–4 months intervals and measurements during the risk and/or 
comparison window were not available for some of the patients. The ACIP also recommends 
Human papillomavirus (HPV) vaccine for HIV-infected persons of 9–26 years old and 
MenACWY vaccine for all HIV-infected persons to prevent meningococcal disease. Because 
the sample size of HIV-infected persons of 9–26 years old in the VSD population was small 
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and the ACIP recommendation for MenACWY for HIV patients occurred after the study 
period, we did not examine AEs following HPV and MenACWY vaccination.
4.1. Public health implications
Among HIV-infected patients with well controlled HIV disease, routinely recommended 
inactivated influenza vaccine, hepatitis B vaccines, Td/Tdap, and PPVS23/PCV13 vaccines 
are generally safe. However, future studies with a larger number of HIV-infected patients 
with high viral load will likely shed more light on whether there is a substantial elevated risk 
for stroke and cerebrovascular diseases following those routine vaccinations among those 
with a HIV RNA viral load greater than 10,000 copies/ml. Nevertheless, given the small 
absolute risk of stroke and cerebrovascular diseases observed in patients with uncontrolled 
HIV disease, health-care providers need to evaluate the benefit of vaccination against severe 
infections and prevent consequent adverse events when considering administering those 
vaccines for HIV-infected patients with a very high HIV RNA viral load.
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Table 3
Relative risk (RR) of stroke and cerebrovascular diseases following vaccination among HIV-infected adults 
with a baseline HIV RNA viral load greater than 10,000 copies/ml, by vaccine type, Vaccine Datalink Project, 
2002–2013.
Vaccine type Number of AE cases RR (95% CI)
Risk
window
Comparison
window
Influenza vaccines (n = 6,693) 7 3 4.3 (0.9–19.7)*
HBV vaccines (n = 1,862) 2 1 2.7 (0.2–30.1)
PPSV23/PCV13 (n = 3,311) 2 1 1.8 (0.1–31.3)*
Td/Tdap (n = 1,300) 1 0 N/A
CI: confidence interval; N/A: not available.
Note: RR was not estimated when there was no AE case during the risk or comparison window.
*Adjusted for seasonality. RR for HBV vaccines were not adjusted for seasonality due to small sample size.
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Table 4
Relative risk (RR) of stroke and cerebrovascular diseases following vaccination with influenza vaccine, 
PPSV23/PCV13, HBV vaccine, and Td/Tdap among HIV-infected adults, based on chart-confirmed new onset 
and recurrent cases, Vaccine Datalink Project, 2002–2013.
Viral load Number of cases Adjusted RR*(95% CI)
Risk
window
Comparison
window
Overall sample 20 46 0.63 (0.36–1.11)
≤200 copies/ml 8 34 0.34 (0.15–0.78)
201–10,000 copies/ml 3 6 0.38 (0.07–2.12)
>10,000 copies/ml 4 4 1.72 (0.41–7.24)#
*
RR: RRs were adjusted for seasonality. CI: confidence interval.
#
Risk difference: 3.5/1,000,000 person-days, 95% CI: [C0]14–21/1,000,000 person-days.
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